• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Medical Device Market
Medical Device News
Medical Device Stocks
  • Medical Device Market
  • Medical Device News
  • Medical Device Stocks
medical device investing

HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock

Gabrielle Lakusta
Jan. 24, 2018 08:59AM PST
Medical Device Investing

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the …

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
As quoted in the press release:

All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC and LifeSci Capital LLC acted as co-managers for the offering.

Click here to read the full press release.

cantor fitzgerald underwritten public offering public offering htg molecular diagnostics molecular diagnostics medical device investing
The Conversation (0)

Go Deeper

AI Powered
A floating DNA double helix above a hand with a blue background.

Top 5 NASDAQ Genetics Stocks (Updated January 2025)

Two graduated cylinders in a lab with blurry orange-capped bottles in the background.

5 Genetic Testing Stocks

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Medical Device Investing Stocks

Cardiex Limited

Cardiex Limited (CDX:AU)
CDX:AU

Cleo Diagnostics

Cleo Diagnostics (COV:AU)
COV:AU

Ocumetics Technology

Ocumetics Technology (OTC:CC)
OTC:CC

Avricore Health

Avricore Health (AVCR:CC)
AVCR:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES